Loading...
•
Dec 31, 2025
Editas Q4 2025 Earnings Report
Net loss narrowed significantly as operating expenses declined following the discontinuation of the reni-cel program.
Key Takeaways
Editas Medicine reported lower collaboration revenue in Q4 2025 while significantly reducing operating expenses after discontinuing the reni-cel program, resulting in a substantially smaller net loss year-over-year. The company continues advancing its lead in vivo candidate EDIT-401 and maintains a strong cash runway into 2027.
Collaboration and other R&D revenue declined to 24741000 from 30604000 year-over-year.
Net loss improved significantly to 5620000 compared with 45395000 in the prior year quarter.
Research and development expenses declined sharply to 27404000 following program discontinuation.
General and administrative expenses decreased to 11353000 due to reduced headcount and lower professional service costs.
Revenue by Segment
Forward Guidance
Editas expects to advance its lead in vivo candidate EDIT-401 toward clinical development in 2026 while maintaining disciplined spending supported by a cash runway into the third quarter of 2027.
Positive Outlook
- Lead candidate EDIT-401 demonstrated over 90% LDL-C reduction in preclinical studies.
- IND/CTA submission for EDIT-401 expected by mid-2026.
- First-in-human clinical trial in HeFH patients planned for 2026.
- Early human proof-of-concept data targeted by year-end 2026.
- Cash runway expected to extend into the third quarter of 2027.
Challenges Ahead
- Revenue declined year-over-year due to fewer milestone payments.
- Company continues to generate operating losses.
- Pipeline progress depends on regulatory clearance for clinical trials.
- Future funding requirements may arise beyond the current cash runway.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...